CAMK2A

Across TCGA pan-cancer cohorts, CAMK2A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CAMK2A data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CAMK2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CAMK2A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, LIHC, and SCLC are the cancer types where CAMK2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	9	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
SCLC	OS	Median	All	0.219	0.706	.011	6	view →
UCEC	DFS	Median	All	0.941	0.609	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CAMK2A–ESCA (OS)

Open the ESCA breakdown →